Azenosertib for Platinum-Resistant Ovarian Cancer

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Recruiting Phase 3 Interventional Study
Ovarian Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
420 (estimated)
Sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Industry
Who this trial is looking for

This trial is looking for women aged 18 or older with specific types of ovarian cancer that have not responded to platinum-based treatments. Participants will receive azenosertib or doctor’s choice of chemotherapy to see how well it works.

Are You a Good Fit for This Trial?
Must be taking BevacizumabPARP inhibitorsMirvetuximab

You may be able to join if

  • I am a woman aged 18 or older
  • I have high-grade serous ovarian, primary peritoneal, or fallopian tube cancer
  • My cancer has measurable disease
  • I have a performance status score of 0 or 1
  • My tumor tests positive for cyclin E1 protein
  • I have received prior treatments and am now platinum-resistant
  • I have had prior treatment with bevacizumab, PARP inhibitors, or mirvetuximab as appropriate
  • I have adequate blood and organ function

You may not be able to join if

  • I have had another type of cancer in the last 2 years, except for some treated cancers
  • I have platinum-refractory disease
  • I have taken azenosertib or other specified inhibitors before
  • I have active, uncontrolled infections
  • I have serious medical conditions affecting my ability to participate
  • I have had major recent surgeries or hospitalizations
  • I am immunocompromised or HIV-positive on specific therapy
  • I have active hepatitis B or C

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Female age ≥ 18 years 2. High-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer 3. Measurable disease per RECIST Version 1.1 4. Eastern Cooperative Oncology Group (ECOG) performance status score 0-1 5. The subject's tumor tissue must be positive fo…
Contacts

Project Director

858.263.4333

medicalaffairs@zentalis.com

CONTACT